Stephen Liu: Characterization of EGFR Mutant NSCLC Transformed to SCLC
Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X…
Read the full articleYou might also wanna read
Expert Panel Discussion on Personalized Decision-Making for HER2-Mutated NSCLC
Get the latest updates on HER2-mutated NSCLC.
mdsc.pe·1d agoEGFR-mutant lung cancer: Cracking the drug resistance code
EGFR-mutant lung cancer: Cracking the drug resistance code Nicole.Raleigh Tue, 14/07/2026 - 08:30
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
Conditions : Non-Small Cell Lung Cancer; Adjuvant Therapy Interventions : Drug: Third-generation EGFR-TKI Sponsors : First Affiliated Hospit
Lung cancer treatments in the era of personalized medicine
Using an individual patient's genetic code helps doctors select treatments most likely to be effective, and that includes for lung cancers,
CME Activity: HER2-Mutated NSCLC Treatment Update
Beyond EGFR and ALK: HER2 mutations represent a growing treatment opportunity in lung cancer. Explore the latest evidence and clinical insig
mdsc.pe·3d agoA Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)
Conditions : Carcinoma, Non-Small-Cell Lung Sponsors : Janssen-Cilag Farmaceutica Ltda. Not yet recruiting
Comments
Sign in to join the conversation.
No comments yet. Be the first.